Can I read Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestones in CML on EtoBox?

Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestones in CML by Martina Murković; Emina Babarović; Blažen Marijić; Dragana Grohovac; Ita Hadžisejdić is a Medicine article available to read on EtoBox.

What is Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestones in CML about?

Chronic myeloid leukemia (CML) is characterized by the fusion gene BCR-ABL1 which encodes aberrantly functioning tyrosine kinase. Treatment with tyrosine kinase inhibitors (TKI) is a landmark of CML management and the main goal is to achieve major molecular response (MMR) which is defined as BCR-ABL1IS ≤ 0.1 % at 12 months of therapy. The aim of this study is to analyze histologic features of bone marrow (BM) in CML patients at the time of diagnosis and compare it to the level of BCR-ABL1IS transcript at 3 (BCR-ABL1IS ≤10 % early molecular response; EMR) and 12 months (MMR) as well as to so called molecularly undetectable leukemia (MUL) to see weather bone marrow morphology can be of value in predicting achievement molecular response milestones. Thirty-two bone marrow biopsies of CML patients, prior TKI therapy, were re-evaluated and CD34 immunohistochemistry was performed to examine microvessel density (MVD) and microvessel area (MVA) and subsequently compared it to the level of BCR-ABL1IS transcript. This study showed statistically significant association between BM hypercellularity and EMR (p = 0.048) and MUL (p = 0.034), peri-trabecular adipocyte distribution and EMR and MUL (p

Who reads Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestones in CML?

Author

Martina Murković; Emina Babarović; Blažen Marijić; Dragana Grohovac; Ita Hadžisejdić

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)